Literature DB >> 1473579

Piroxicam-induced analgesia: evidence for a central component which is not opioid mediated.

A Fabbri1, G Cruccu, P Sperti, M Ridolfi, T Ciampani, M G Leardi, S Ferracuti, V Bonifacio.   

Abstract

Piroxicam is a nonsteroidal anti-inflammatory drug with a potent analgesic effect. In order to establish whether the analgesic action of Piroxicam has a central component, we studied the effect of the drug on the nociceptive orbicularis oculi reflexes evoked by electrical stimulation of the cornea and supraorbital nerve in healthy subjects. Piroxicam significantly suppressed the corneal reflex and R3 component of the blink reflex by 28% (p < 0.05) and 50% (p < 0.01), respectively. This effect was not reversed by the i.v. injection of naloxone. Beta-endorphin levels did not change. Piroxicam administration induces distinct inhibitory changes in nociceptive reflexes, which suggests that the analgesic action of the drug has a central component. The ineffectiveness of naloxone, and the lack of beta-endorphin changes, indicate that this central action is independent of the opioid system; other pain regulatory systems are probably involved.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1473579     DOI: 10.1007/bf01948008

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


  21 in total

1.  Nociceptive quality of the orbicularis oculi reflexes as evaluated by distinct opiate- and benzodiazepine-induced changes in man.

Authors:  G Cruccu; S Ferracuti; M G Leardi; A Fabbri; M Manfredi
Journal:  Brain Res       Date:  1991-08-16       Impact factor: 3.252

2.  Beta-endorphin production by the fetal Leydig cell: regulation and implications for paracrine control of Sertoli cell function.

Authors:  A Fabbri; G Knox; E Buczko; M L Dufau
Journal:  Endocrinology       Date:  1988-02       Impact factor: 4.736

3.  Excitability of the corneal reflex in man.

Authors:  G Cruccu; R Agostino; A Berardelli; M Manfredi
Journal:  Neurosci Lett       Date:  1986-01-30       Impact factor: 3.046

4.  A pharmacological distinction between the long and short latency pathways of the human blink reflex revealed with tobacco.

Authors:  C Evinger; P A Sibony; K A Manning; R A Fiero
Journal:  Exp Brain Res       Date:  1988       Impact factor: 1.972

5.  Evidence of a central component in the analgesic effect of indoprofene.

Authors:  C Paeile; M C Lombard; H Saavedra; E Bustos; T Pelissier
Journal:  Gen Pharmacol       Date:  1989

6.  Diclofenac and pirprofen modify pituitary and hypothalamic beta-endorphin concentrations.

Authors:  P Sacerdote; G Monza; P Mantegazza; A E Panerai
Journal:  Pharmacol Res Commun       Date:  1985-08

7.  Effect of aspirin on serotonin and met-enkephalin in brain: correlation with the antinociceptive activity of the drug.

Authors:  A Groppetti; P C Braga; G Biella; M Parenti; L Rusconi; P Mantegazza
Journal:  Neuropharmacology       Date:  1988-05       Impact factor: 5.250

8.  Modes of action of aspirin-like drugs.

Authors:  S Abramson; H Korchak; R Ludewig; H Edelson; K Haines; R I Levin; R Herman; L Rider; S Kimmel; G Weissmann
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

9.  Aspirin analgesia evaluated by event-related potentials in man: possible central action in brain.

Authors:  A C Chen; C R Chapman
Journal:  Exp Brain Res       Date:  1980       Impact factor: 1.972

10.  Diclofenac increases beta-endorphin plasma concentrations.

Authors:  A Martini; G P Bondiolotti; P Sacerdote; L Pierro; G B Picotti; A E Panerai; L Restelli; F Zancaner; G Monza
Journal:  J Int Med Res       Date:  1984       Impact factor: 1.671

View more
  2 in total

Review 1.  Differential analgesic effects of aspirin-like drugs.

Authors:  K Brune; S Menzel-Soglowek; H U Zeilhofer
Journal:  Drugs       Date:  1992       Impact factor: 9.546

2.  Analgesic efficacy of non-steroidal anti-inflammatory drugs in experimental pain in humans.

Authors:  J S Walker; J F Arroyo; T Nguyen; R O Day
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.